Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Pentoxifylline 400 mg Oral Tablet — DRUG
  Pentoxifylline 400 mg capsule will be taken orally twice daily after meals, once in the morning and once in the evening, for 12 weeks. The intervention will be given as add-on therapy while participants continue standard topical treatment for plaque psoriasis.
• Placebo — DRUG
  Matching placebo capsule will be taken orally twice daily after meals, once in the morning and once in the evening, for 12 weeks. The placebo will be given as add-on therapy while participants continue standard topical treatment for plaque psoriasis.

Study Details

This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.

Key Dates

First listed

Jun 4, 2026

Start date

Jun 15, 2026

Status verified

Jun 2026

Primary completion

Mar 31, 2027

Completion

Oct 31, 2028

Study Design

Enrollment

140 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Pentoxifylline Add-On Therapy
  Participants in this arm will receive pentoxifylline 400 mg orally twice daily after meals for 12 weeks, in addition to standard topical therapy for plaque psoriasis. Participants will continue their usual standard topical treatment according to clinical care. Follow-up assessments will be performed through week 16.
• Placebo Comparator: Placebo Add-On Therapy
  Participants in this arm will receive matching placebo orally twice daily after meals for 12 weeks, in addition to standard topical therapy for plaque psoriasis. Participants will continue their usual standard topical treatment according to clinical care. Follow-up assessments will be performed through week 16.

Primary Outcome Measure

Proportion of Participants Achieving PASI 50 [ Time Frame: Week 12 ]

Central Contacts

• Wasuchon Chaichan, MD
  +66949749616
  [email protected]
• Chonlawat Chaichan, MSc
  [email protected]

Find similar trials

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Regulation of Inflammatory Genes in Psoriasis
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey